Role of HER 2 Expression in Premalignant and Malignant Lesions of Uterine Cervix

Vijayalakshmi, M (2020) Role of HER 2 Expression in Premalignant and Malignant Lesions of Uterine Cervix. Masters thesis, Madurai Medical College, Madurai.

[img]
Preview
Text
200300320vijayalakshmi.pdf

Download (11MB) | Preview

Abstract

INTRODUCTION: Cervical carcinoma ranks second most common malignancy in India. India alone contributes 25.41% of the global burden of cervical carcinoma cases. 26.48% of global mortality occurs in India. Cervical carcinoma is unique, as unlike other tumors it can be identified in its precancerous lesion and treated, thus preventing potential progression to cervical carcinomas. 67,477 deaths occur annually with approximately 185 women die every day, 8 women die every hour and every 8 minutes a women dies. There are several prognostic factors including age, size of tumor, FIGO stage, involvement of parametrium and vagina and nodal status. Researches have been made on various biomarkers for assessing the prognosis and in search for targeted therapies. In our study, we analyse the role of HER 2 in premalignant and malignant lesions of cervix and its correlation with clinicopathological parameters. AIMS AND OBJECTIVES: 1. To study the histomorphological features of cervical lesions - premalignant lesions (LSIL and HSIL) and malignant lesion. 2. To evaluate the expression of HER-2/neu in cervical lesions. 3. To correlate histomorphology of cervical lesions with HER-2/neu in cervical lesions. MATERIALS AND METHODS 200 cases were included in the study, paraffin embedded blocks are cut and stained with hematoxyillin and eosin stains. Out of 200 cases, 50 cases were selected and immunostaining with HER 2 was done and intensity of staining was scored and correlated with cliniomorphological variables. RESULTS: In our study, when age of patients were compared with premalignant and malignant lesions, it was observed that premalignant lesion presented at an earlier age as compared to malignant lesions, which presented at late stages. On comparing the menstrual status and the stage of carcinoma, it was observed that postmenopausal female presented in advanced stage of carcinoma and menstruating female in early stages. Statistically significant correlation was made with p value of less than 0.001. In our study, HER 2 expression was higher in malignant lesion as compared to premalignant lesion of cervix. The p value was less 0.001, hence significant correlation was made out. The intensity score of HER 2 was greater with increasing grades of cervical carcinoma. Overexpression of HER 2 was observed in advanced stages with increased expression of HER 2 seen in tumors of larger size. The correlation was statistically significant with p value less than 0.001. CONCLUSION: In our study, expression of HER 2 correlated with many of the clinicopathological variables, which were considered as poor prognostic factor. Hence, the study can be concluded by suggesting that HER 2 can be considered as one of the poor prognostic factor and research studies should be done in considering HER 2 as a therapeutic target.

Item Type: Thesis (Masters)
Additional Information: 201713102
Uncontrolled Keywords: HER 2/neu, cervical carcinoma, FIGO.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jan 2021 16:17
Last Modified: 29 Jan 2021 16:17
URI: http://repository-tnmgrmu.ac.in/id/eprint/13404

Actions (login required)

View Item View Item